Meeting
2021 ASCO Annual Meeting
Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors.
Authors
Maura L. Gillison
The University of Texas MD Anderson Cancer Center, Houston, TX
Maura L. Gillison , Mark M. Awad , Przemyslaw Twardowski , Ammar Sukari , Melissa Lynne Johnson , Mark N. Stein , Richard Hernandez , Jessica Price , Kevin J. Mancini , Mara Shainheit , Vijetha Vemulapalli , Jessica Flechtner , Thomas A. Davis , Roger B. Cohen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Vaccines
Clinical Trial Registration Number
NCT03633110
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2613)
DOI
10.1200/JCO.2021.39.15_suppl.2613
Abstract #
2613
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Updated results from an ongoing phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via IT injection as monotherapy or combined with pembrolizumab in advanced solid tumors.
First Author: Jiaxin Niu
Poster
2023 ASCO Annual Meeting
Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma.
First Author: Jiajian Liu
Poster
2022 ASCO Annual Meeting
A phase 1 multiple-ascending dose study to evaluate the safety and tolerability of XmAb23104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (DUET-3).
First Author: Mehmet Akce
Poster
2022 ASCO Annual Meeting
A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6.
First Author: Gerald Steven Falchook